Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: Major Tom who wrote (1817)	10/5/1998 8:27:00 PM
From: Andrew T	Read Replies (1) \| Respond to of 4650

Here is some news: ------------------------------------------------------------------------ FOR IMMEDIATE RELEASE Contact: Dr. Jeff Garwin BioModa Inc. Phone: 888-848-8594 Email: info@biomoda.com Web Site: biomoda.com Medical / Business News FOREIGN PATENTS ISSUE ON LUNG CANCER TECHNOLOGY [Albuquerque, New Mexico 10/2/98]. BioModa Inc. announced today that patents covering its worldwide, exclusively licensed technology have issued in Australia, Korea, and the Russian Federation. Claims were approved that protect BioModa's exclusive right to use TCPP to screen for lung cancer in sputum samples. Other approved claims protect BioModa's exclusive right to use radioactive Copper bound to TCPP for imaging lung cancer in patients, as well as for treating lung cancer in patients. Additional patents are pending in Europe, Asia, and South America. "These approvals validate and enhance the value of our technology," states BioModa's Chief Technical Officer, Jeff Garwin, M.D., Ph.D. "BioModa is a leader in developing integrated disease management for lung cancer, with a coherent technology to diagnose, image, treat and monitor patients with the disease." The core technology was licensed in 1995 from the University of California, through the Industrial Partnership Office of the Los Alamos National Laboratory. The license is an exclusive, worldwide license. "BioModa plans to file additional patent applications within the next 18 months, to enhance the market value of products in development," says Dr. Garwin.

To: Major Tom who wrote (1817)	10/5/1998 8:31:00 PM
From: Andrew T	Read Replies (1) \| Respond to of 4650

Old news with some qoutes From Biomoda: ------------------------------------------------------------------------ FOR IMMEDIATE RELEASE Contact: Dr. Jeff Garwin BioModa Inc. Phone: 888-848-8594 Email: info@biomoda.com Web Site: biomoda.com MEDICAL / BUSINESS NEWS TESTING BEGINS ON NEW TEST FOR EARLY DETECTION OF LUNG CANCER [Albuquerque, New Mexico, 10/1/98] A new screening test called TCPP, which may provide lung cancer detection 5 to 7 years earlier than current diagnostic tools, has begun human trials in a commercial setting this month. BioModa Inc. contracted with a commercial lung cytology laboratory to perform process optimization work on the TCPP test, which can detect cancer cells in sputum samples. This work has been completed. The laboratory will now conduct a study comparing BioModa's patented TCPP technology with current state-of-the-art cytopathology, expecting to complete the study before the end of October 1998. 90% of lung cancer victims are smokers, and each day 471 Americans are diagnosed with the disease. Each day in the U.S. 420 lung cancer victims die from the disease, a survival rate of 15%. Early detection of the disease could raise the survival rate of these people to 85%, but current tests cannot detect the disease early enough. The new TCPP screening test may provide the lifesaving advantage of early detection. The test is performed on sputum, lung secretions that are coughed up by smokers or other individuals at risk for lung cancer. "We set out to increase the survival rate of people with lung cancer by detecting the disease early," states BioModa's Chief Technical Officer, Jeff Garwin, M.D., Ph.D. "This new technology may not only provide early detection, but may also provide more efficient ways to treat and manage lung cancer. This integrated disease management approach is at the cutting edge of biomedical research." Dr. Edward Ellinwood and his colleagues, at Los Alamos National Laboratory and St. Mary's Hospital, recognized that special porphyrins, a class of molecules that occur commonly in the human body, could be used to detect, locate, and treat lung cancer. Locating and treating lung cancer in the body could be accomplished by binding radioactive atoms to the porphyrin molecules. These radioactive porphyrins would find and penetrate cancer cells. With this "cancer detector", doctors could locate and kill lung cancer cells in the patient's body, with minimum damage to surrounding cells. "In 1995, our company created a licensing partnership with Los Alamos National Laboratory in New Mexico," states BioModa's President Ari Ma'ayan. "We are nearing our goal of marketing the first technology useful for large scale screening for lung cancer. We would like this to be a 'Pap smear for smokers.'"

To: Major Tom who wrote (1817)	10/5/1998 8:38:00 PM
From: Andrew T	Respond to of 4650

Actually, it soounds like the tests with Lungcheck may be complete! <<< BioModa Inc. contracted with a commercial lung cytology laboratory to perform process optimization work on the TCPP test, which can detect cancer cells in sputum samples. This work has been completed. The laboratory will now conduct a study comparing BioModa's patented TCPP technology with current state-of-the-art cytopathology, expecting to complete the study before the end of October 1998. >>>>>> Appears that it may be off to: <<<These results will be sent for confirmation to a prestigious institution on the East coast, with further confirmation expected by the first week in October. Verified results will be submitted to various medical journals for publication as well as to the national media. >> from ADOT press release on 9/9/98